Boston Scientific (BSX) Q3 Earnings and Revenues Top Estimates

Core Insights - Boston Scientific reported quarterly earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, and showing an increase from $0.63 per share a year ago, resulting in an earnings surprise of +5.63% [1] - The company achieved revenues of $5.07 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.94%, and up from $4.21 billion year-over-year [2] - Boston Scientific has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise of +5.63% indicates strong performance relative to expectations, with a previous quarter's surprise of +4.17% [1][2] - The company has maintained a favorable trend in estimate revisions leading up to the earnings release, contributing to a Zacks Rank 2 (Buy) for the stock [6] Future Outlook - Current consensus EPS estimate for the upcoming quarter is $0.76 on revenues of $5.16 billion, and for the current fiscal year, it is $2.98 on revenues of $19.85 billion [7] - The sustainability of stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] Industry Context - The Medical - Products industry, to which Boston Scientific belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can significantly affect stock performance [5][8]